Medication info

Idalbiclo Tablets 40/12.5 mg

Prescription medicationTabletOralApproval withdrawn
Ingredient · strength
Potassium Azilsartan Medoxomil›42.68mg / 1 tabletChlorthalidone›12.5mg / 1 tablet
Manufacturer / importer
Celltrion Pharm, Inc.
Appearance
Light red, round, biconvex film-coated tablet
Packaging
28 tablets (14 tablets/PTP X 2), 56 tablets (14 tablets/PTP X 4)
Approval status
Approval withdrawn

MFDS item code 201803207 · Approved 2018.08.06 · Insurance code 693903470

This product's status changed to Approval withdrawn on 2024.05.13. It may no longer be sold, so consult a doctor or pharmacist before taking it.

Summary

Main use
Initial treatment of uncontrolled essential hypertension on monotherapy and stage 2 hypertension
Who takes it
Adults · Children
Adult dose
1. Adults The recommended initial dose of this medicine is 40/12.5 milligrams, taken with water, with or without food. The blood pressure-lowering effect is evident in most patients within 1-2 weeks. If blood pressure control is needed after 2-4 weeks, the dose may be increased to 40/25 milligrams. Doses exceeding 40/25 milligrams are not useful. 1) Patients whose blood pressure is not adequately controlled with monotherapy: It is recommended to adjust the dose of azilsartan medoxomil before administering this medicine. For patients whose blood pressure is not adequately controlled with azilsartan medoxomil monotherapy, switching to this medicine may be considered; the recommended initial dose is 40/12.5 milligrams once daily. 2) When this medicine is administered as initial therapy to patients with stage 2 hypertension, the decision should be based on an assessment of the potential benefits and risks, including whether the patient can tolerate the initial dose. The recommended initial dose is 40/12.5 milligrams once daily. 2. Older adults No dose adjustment is needed when administering this medicine to older adults. Although no overall differences in safety or efficacy were observed between older and younger patients, greater sensitivity in some older adults cannot be ruled out. 3. Patients with renal impairment No dose adjustment is needed in patients with mild or moderate renal impairment. 4. Patients with hepatic impairment Experience with this medicine is limited; however, based on clinical results for azilsartan medoxomil, no dose adjustment is needed in patients with mild or moderate hepatic impairment. 5. Patients with intravascular volume depletion For patients with salt depletion or possible volume depletion (e.g., those with vomiting or diarrhea, or receiving high doses of diuretics), correct the volume depletion before starting this medicine, and initiate treatment under close medical supervision.
Child dose
The safety and efficacy of this drug have not been established in children and adolescents under 18 years of age.

Ingredients

Importer
Celltrion Pharm, Inc.

Efficacy & effects

Initial treatment of uncontrolled essential hypertension on monotherapy and stage 2 hypertension

  • Essential hypertension
  • stage 2 hypertension
View approved original text

Azilsartan Medoxomil is used in patients with essential hypertension who find it difficult to control blood pressure with monotherapy. It also aids as initial therapy when combination therapy is needed in stage 2 hypertension patients. This drug effectively lowers blood pressure, helping to improve hypertension management.

How to take

Adult dose

1. Adults The recommended initial dose of this medicine is 40/12.5 milligrams, taken with water, with or without food. The blood pressure-lowering effect is evident in most patients within 1-2 weeks. If blood pressure control is needed after 2-4 weeks, the dose may be increased to 40/25 milligrams. Doses exceeding 40/25 milligrams are not useful. 1) Patients whose blood pressure is not adequately controlled with monotherapy: It is recommended to adjust the dose of azilsartan medoxomil before administering this medicine. For patients whose blood pressure is not adequately controlled with azilsartan medoxomil monotherapy, switching to this medicine may be considered; the recommended initial dose is 40/12.5 milligrams once daily. 2) When this medicine is administered as initial therapy to patients with stage 2 hypertension, the decision should be based on an assessment of the potential benefits and risks, including whether the patient can tolerate the initial dose. The recommended initial dose is 40/12.5 milligrams once daily. 2. Older adults No dose adjustment is needed when administering this medicine to older adults. Although no overall differences in safety or efficacy were observed between older and younger patients, greater sensitivity in some older adults cannot be ruled out. 3. Patients with renal impairment No dose adjustment is needed in patients with mild or moderate renal impairment. 4. Patients with hepatic impairment Experience with this medicine is limited; however, based on clinical results for azilsartan medoxomil, no dose adjustment is needed in patients with mild or moderate hepatic impairment. 5. Patients with intravascular volume depletion For patients with salt depletion or possible volume depletion (e.g., those with vomiting or diarrhea, or receiving high doses of diuretics), correct the volume depletion before starting this medicine, and initiate treatment under close medical supervision.

Child dose

The safety and efficacy of this drug have not been established in children and adolescents under 18 years of age.

Precautions

This medication should be discontinued in pregnant women, as it can cause serious harm to the fetus and newborn during the second and third trimesters. Patients with impaired liver function or ongoing liver disease should exercise caution, as this medication can cause serious issues such as hepatic coma. Severely renal impaired patients may experience elevated blood nitrogen levels due to the diuretic component of this drug, risking side effects from drug accumulation. Those with allergies to this drug or its components, pregnant or potentially pregnant women, and nursing mothers should not take this medication. Patients with anuria, severe hepatic impairment, or renal impairment, as well as those with hyponatremia or hypercalcemia, should also avoid this drug. Patients with a history of gout or hyperuricemia, those undergoing lithium treatment, or those taking medications that pose a risk of specific cardiac arrhythmias need to be cautious when taking this medication. In states of low blood volume or sodium depletion, hypotension symptoms may occur during early treatment; therefore, correction of the condition before use and immediate lying down in case of hypotension is necessary. Patients with impaired kidney function should have their renal function regularly monitored during treatment and discontinue use if deterioration occurs. Due to a lack of established safety in severely impaired hepatic patients, caution is advised when administering this drug. This medication may cause electrolyte imbalances such as hypokalemia, hyponatremia, and hypercalcemia, so frequent blood tests to check electrolyte levels are necessary. Hypokalemia, in particular, can be risky for patients with heart disease, so caution is required. Patients with hyperuricemia or gout may experience worsened symptoms when taking this drug; avoiding it is recommended. When used with other antihypertensive agents, the risk of hypotension, hyperkalemia, and renal function decline may increase, so combinations should be avoided or used with caution. Consult healthcare professionals immediately if blood pressure drops too low or there are renal function issues. Dizziness or drowsiness may occur during use; caution is needed when driving or operating heavy machinery. Adverse reactions may include increased serum creatinine, dizziness, hypotension, diarrhea, nausea, rash, etc.; if symptoms are severe or persistent, notify healthcare professionals. Pregnant or planning to become pregnant women should refrain from taking this medication, and it is not recommended for nursing mothers. In case of overdose, symptoms like hypotension, dizziness, and electrolyte imbalance may occur, so immediate medical attention is required. This medication should be stored out of reach of children and kept in its original packaging, away from light and moisture.

Side effects

  • Anemia
  • increased blood uric acid
  • hyperuricemia
  • hypokalemia
  • increased blood potassium
  • hyponatremia
  • decreased blood sodium
  • gout
  • dizziness
  • orthostatic dizziness
Show 84 more
  • syncope
  • paresthesia
  • hypotension
  • diarrhea
  • nausea
  • vomiting
  • rash
  • pruritus
  • muscle cramps
  • fatigue
  • increased blood creatinine
  • increased blood urea
  • increased blood sugar
  • peripheral edema
  • migraine
  • increased blood creatine phosphokinase
  • renal impairment
  • severe angioedema
  • thrombocytopenia
  • leukopenia
  • agranulocytosis
  • eosinophilia
  • elevated blood lipids
  • hypomagnesemia
  • hypercalcemia
  • diabetes
  • worsening of diabetic metabolic state
  • hypochloremic alkalosis
  • headache
  • orthostatic hypotension
  • cardiac arrhythmia
  • idiopathic pulmonary edema
  • loss of appetite
  • mild gastrointestinal disturbances
  • constipation
  • stomach pain
  • pancreatitis
  • intrahepatic bile stagnation or jaundice
  • hives
  • photosensitivity reactions
  • cutaneous vasculitis
  • allergic interstitial nephritis
  • weakness
  • renal impairment
  • renal failure
  • increased serum creatinine
  • increased serum uric acid
  • decreased hematocrit
  • decreased hemoglobin levels
  • decreased red blood cell count
  • dizziness
  • syncope
  • total syncope
  • constipation
  • vomiting
  • bad breath
  • weakness
  • dyspnea
  • dyslipidemia
  • hypercholesterolemia
  • gout
  • hyperkalemia
  • arthralgia
  • myalgia
  • musculoskeletal stiffness
  • increased aspartate aminotransferase
  • urinary tract infection
  • upper respiratory infection
  • acute kidney injury
  • diabetic nephropathy
  • dermatitis
  • hives
  • hair loss
  • subdural hematoma
  • irregular menstruation
  • worsening of hypertension
  • chest pain
  • palpitations
  • tremor
  • increased serum triglycerides
  • hyperkalemia
  • palpitations
  • hypotension
  • worsening of hypertension

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly sealed container protected from light, ideally at a temperature between 1 to 30 degrees Celsius in a room. It should also be kept in a dry place to maintain its effectiveness.

Appearance and packaging

Appearance

Light red, round, biconvex film-coated tablet

Package unit

28 tablets (14 tablets/PTP X 2), 56 tablets (14 tablets/PTP X 4)

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.